This HTML5 document contains 53 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n10http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/pharmgkb/
n13http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/pubchem-compound/
admshttp://www.w3.org/ns/adms#
n8http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/pubchem-substance/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/kegg-drug/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/sukl/drug/
n15http://linked.opendata.cz/resource/atc/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01621/identifier/chemspider/

Statements

Subject Item
n2:DB01621
rdf:type
n3:Drug
n3:description
Pipotiazine has actions similar to those of other phenothiazines. Among the different phenothiazine derivatives, it appears to be less sedating and to have a weak propensity for causing hypotension or potentiating the effects of CNS depressants and anesthetics. However, it produces a high incidence of extra pyramidal reactions. It is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
n3:group
approved
n3:indication
For the maintenance treatment of chronic non-agitated schizophrenic patients.
owl:sameAs
n13:DB01621 n16:DB01621
dcterms:title
Pipotiazine
adms:identifier
n6:56598 n7:62867 n8:46508263 n9:D08385 n10:PA10158 n18:DB01621
n3:mechanismOfAction
Pipotiazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects).
n3:synonym
Piportil Pipothiazine Pipotiazina Pipotiazinum
n3:toxicity
Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
n3:foodInteraction
Avoid alcohol Take with food to decrease irritation
n3:IUPAC-Name
n4:271B5D19-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D1F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D1E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D1B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D1C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D1D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5D17-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D15-363D-11E5-9242-09173F13E4C5 n4:271B5D18-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5D16-363D-11E5-9242-09173F13E4C5
n14:hasATCCode
n15:N05AC04
n3:H-Bond-Acceptor-Count
n4:271B5D25-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D26-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D20-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D21-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D23-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D22-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D24-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
39860-99-6
n3:category
n3:containedIn
n11:271B5D14-363D-11E5-9242-09173F13E4C5 n11:271B5D13-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5D2B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D2D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D2E-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D2A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D29-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D2C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D1A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5D27-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D28-363D-11E5-9242-09173F13E4C5